3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
3
Stomach Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Endometrial Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Paclitaxel
3
Oxaliplatin
3
Leucovorin
3
Fluorouracil
3
Docetaxel
3
Capecitabine
3
zolbetuximab
2
trastuzumab deruxtecan
2
pembrolizumab
2
enzalutamide
2
darolutamide
2
Ramucirumab
2
Nivolumab
2
Irinotecan
2
trifluridine tipiracil drug combination
1
repotrectinib
1
regorafenib
1
lenvatinib
1
ipatasertib
1
fludarabine
1
durvalumab
1
atezolizumab
1
apalutamide
1
aldesleukin
1
abiraterone
1
X-Rays
1
Vinorelbine
1
Trifluridine
1
Radiosurgery
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
ipatasertib
×
30 days
×
Clear all
NCT04739202
2026-06-09
IMMUNOGAST
Hospices Civils de Lyon
Phase 2
Completed
54 enrolled